Introduction

Objective
N Venous thromboembolism (VTE: the composite of deep vein thrombosis [DVT] and pulmonary embolism [PE]
) is the outcome of a clot, which forms within a vein and then travels through the blood vessels to a different site N Total knee replacement (TKR) surgery is an important risk factor for VTE 1 N With more than 66,000 TKRs being performed in the UK 2 and almost 17,000 being performed in Spain annually, the potential impact is large 3 N Rivaroxaban is a novel, once-daily, direct inhibitor of Factor Xa that received marketing approval in the EU and in Canada for the prevention of VTE after elective TKR and total hip replacement. Unlike existing low molecular weight heparins such as enoxaparin, rivaroxaban is administered orally N The efficacy and tolerability of rivaroxaban against enoxaparin, both for 14 days, in VTE prevention after TKR was demonstrated in two large, multi-country, randomized clinical trials (RECORD3 4 and RECORD4
5
) N The enoxaparin dose used in RECORD4 (30 mg twice daily) is primarily used in North America, and so while RECORD4 results support those of RECORD3, the data are excluded from this analysis N In RECORD3, rivaroxaban reduced total VTE (composite of any DVT, non-fatal PE and all-cause mortality) by 49% and symptomatic VTE by 66% versus enoxaparin. 4 There was a similar level of major bleeding in both arms Table 2 ). The analyses also show that rivaroxaban remains cost-saving and more efficacious when long-term complications are excluded N Probabilistic sensitivity analyses show that dominance is maintained in 100% of cases in both the UK (Figure 3 ) and Spain ( Figure 4 ) N These results demonstrate that baseline results are reliable and withstand changes to the value of key variables 
Long-term complications period
N Event probabilities during prophylaxis were derived from RECORD3 data. The probability of asymptomatic events developing into symptomatic events after prophylaxis was based on published clinical data. 6 The estimated risks of VTE, CTPH and PTS beyond the initial 90 days after surgery were based on epidemiological data 7, 8 N Resource consumption and associated costs of symptomatic events (2008 pounds [£] in the UK, euros [€] in Spain) were derived from published sources (Table 1) 1,9-20 N In the UK, the fact that rivaroxaban is an oral drug with no monitoring requirements resulted in the following savings -8% of patients require daily nurse visits to inject subcutaneous enoxaparin (the remainder self-inject), at £24 per visit 1, 9 -While in hospital, enoxaparin patients require a full blood count at baseline and then every 2-4 days until 14 days, at £2.35 per test 1, 9 N These savings are not realized in Spain because these resources are not allocated for Spanish patients N Utilities were taken from a systematic literature review, which provided the utility associated with DVT and PE 21 and long-term complications. 22 Both utilities were adjusted for the fact that patients had undergone TKR 23 N Costs and outcomes beyond the first year were discounted at 3.5% per annum in the UK and 3%
per annum in Spain. Probabilistic sensitivity analyses were conducted. Event probabilities and utilities used a beta distribution, whereas costs used either a normal or gamma distribution Incremental cost
